Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study.
fecal microbiota transplantation
serial infusions
ulcerative colitis
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
02
08
2023
revised:
26
09
2023
accepted:
06
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The effectiveness of fecal microbiota transplantation (FMT) in ulcerative colitis (UC) remains unclear. This study aimed to investigate the feasibility and effectiveness of serial fecal infusions via colonoscopy in patients with active UC. Subjects with mild-to-moderate UC received three consecutive fecal infusions via colonoscopy. A control population with the same baseline features receiving Infliximab treatment was enrolled. Adverse events and clinical, endoscopic, and microbial outcomes were investigated. Nineteen patients with mildly-to-moderately active UC were enrolled. Clinical response was obtained in six patients at week 2, in eight at week 6, and in nine at week 12. Clinical response was maintained in eight patients at week 24. Endoscopic remission at week 12 was reached in six patients. In the control population, 13/19 patients achieved clinical response at week 6, and 10/19 patients maintained clinical response after 6 months. Microbiota richness was higher in responders compared with the non-responders.
Identifiants
pubmed: 37894194
pii: microorganisms11102536
doi: 10.3390/microorganisms11102536
pmc: PMC10609093
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):141-151
pubmed: 34863330
Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26
pubmed: 24118601
Am J Gastroenterol. 2013 Apr;108(4):500-8
pubmed: 23511459
Gut. 2023 Sep;72(9):1642-1650
pubmed: 37339849
PLoS One. 2021 Apr 9;16(4):e0249861
pubmed: 33836037
JAMA. 2016 Jan 12;315(2):142-9
pubmed: 26757463
PLoS One. 2015 Aug 19;10(8):e0133925
pubmed: 26288277
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
J Gastroenterol. 2018 Jan;53(1):95-106
pubmed: 28852861
Ann Intern Med. 2016 Nov 01;165(9):609-616
pubmed: 27547925
Lancet. 2017 Apr 29;389(10080):1710-1718
pubmed: 28259484
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Nutrients. 2021 Nov 23;13(12):
pubmed: 34959740
Lancet. 2017 Mar 25;389(10075):1218-1228
pubmed: 28214091
Gastroenterology. 2015 Jul;149(1):110-118.e4
pubmed: 25836986
JAMA. 2017 Nov 28;318(20):1985-1993
pubmed: 29183074
Front Immunol. 2022 Jul 07;13:934695
pubmed: 35874661
PLoS Comput Biol. 2012;8(9):e1002687
pubmed: 23028285
Nat Rev Gastroenterol Hepatol. 2016 Sep;13(9):508-16
pubmed: 27329806
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Cytokine. 2012 Sep;59(3):451-9
pubmed: 22795953
Front Cell Infect Microbiol. 2020 Feb 25;10:59
pubmed: 32158700
Curr Opin Biotechnol. 2018 Feb;49:140-147
pubmed: 28866243
Aliment Pharmacol Ther. 2017 Sep;46(5):479-493
pubmed: 28707337
Pathogens. 2023 Feb 06;12(2):
pubmed: 36839534
Br J Cancer. 2022 May;126(9):1318-1328
pubmed: 35292756
Pharmacol Ther. 2015 May;149:191-212
pubmed: 25561343
Gut. 2014 Aug;63(8):1275-83
pubmed: 24021287
Am J Gastroenterol. 2013 Oct;108(10):1620-30
pubmed: 24060759
Aliment Pharmacol Ther. 2015 May;41(9):835-43
pubmed: 25728808
United European Gastroenterol J. 2018 Oct;6(8):1232-1244
pubmed: 30288286
Nat Protoc. 2020 Mar;15(3):799-821
pubmed: 31942082
Gastroenterology. 2015 Jul;149(1):102-109.e6
pubmed: 25857665
Front Immunol. 2022 Feb 14;13:836542
pubmed: 35237276
JAMA. 2019 Jan 15;321(2):156-164
pubmed: 30644982
Inflamm Bowel Dis. 2013 Sep;19(10):2155-65
pubmed: 23899544
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188
pubmed: 28449106
BMC Gastroenterol. 2021 Jul 8;21(1):281
pubmed: 34238227